Percutaneous intervention in portosystemic shunts in Budd-Chiari syndrome.
Budd-Chiari syndrome is a rare, often fatal illness resulting from hepatic venous outflow obstruction. Surgically created portosystemic shunts are frequently necessary in these patients for portal decompression. Over the past 15 years, 30 patients have been surgically treated for this condition at the Johns Hopkins Hospital. Of the 22 long-term survivors (range, 6 months to 13 years), five (23%) have required further surgical intervention and five (23%) have required percutaneous intervention for shunt complications. Percutaneous procedures included angioplasty (n = 10), atherectomy (n = 1), and urokinase therapy (n = 1). Of the five patients treated percutaneously, one has died of complications from her disease. The remaining four have been followed up for a mean of 16.2 months (range, 5-31 months) and all are in stable condition. None of the five treated with percutaneous interventional procedures have required additional surgical procedures or shunt revisions. Although this series is small, the findings indicate that percutaneous intervention may play a strong adjunctive role to surgery in the treatment of selected patients with portosystemic shunt complications.
Savader
S J
SJ
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21205.
Venbrux
A C
AC
Klein
A S
AS
Osterman
F A
FA
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon; D001161:Arteriosclerosis / Q000601:surgery; D006502:Budd-Chiari Syndrome / Q000453:epidemiology / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011170:Portasystemic Shunt, Surgical / Q000009:adverse effects*; D012189:Retrospective Studies; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
D014568:Urokinase-Type Plasminogen Activator